Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group.
about
Current and emerging azole antifungal agentsHistoplasmosis: a clinical and laboratory updateActivities of sordarins in murine histoplasmosisIn vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeastsClearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerTreatment of histoplasmosis with MK-991 (L-743,872)Detection of the 70-kilodalton histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-upComparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS.Gastrointestinal histoplasmosis in patients with AIDS: case report and review.Itraconazole.Endemic mycosis complicating human immunodeficiency virus infection.Intravenous itraconazole.[Histoplasmosis].Management of histoplasmosis.Histoplasmosis Masquerading as a Rheumatoid Nodule in an Immunocompromised Host: A Case Report.Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum.Challenges in the management of disseminated progressive histoplasmosis in human immunodeficiency virus-infected patients in resource-limited settings.Detection of histoplasma antigen by a quantitative enzyme immunoassayImprovements in diagnosis of histoplasmosis.Clinical pharmacology of antifungal agents in pediatric patients.Emerging disease issues and fungal pathogens associated with HIV infectionDefining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realizedUnmasking histoplasmosis immune reconstitution inflammatory syndrome in a patient recently started on antiretroviral therapy.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Histoplasmosis in the nasal septum without pulmonary involvement in a patient with acquired immunodeficiency syndrome: case report and literature review.Management of fungal lung disease in the immunocompromised.Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Localised oral histoplasmosis lesions associated with HIV infection.Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.Histoplasma capsulatum yeast phase-specific protein Yps3p induces Toll-like receptor 2 signaling.Comparison of radioimmunoassay and enzyme-linked immunoassay methods for detection of Histoplasma capsulatum var. capsulatum antigen.Progressive disseminated histoplasmosis presenting with cachexia and hypercalcemia.Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps.Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassayImproved detection of Histoplasma antigenemia following dissociation of immune complexes.
P2860
Q24550733-2E584378-FF1A-4835-96E1-A09AA72B0DD5Q24675642-17BAA32D-7A62-4DCA-AF28-517D9D7D22EDQ28343419-986E552D-45AE-43EF-A5DD-379DB6F6E84BQ28379385-95C88886-C883-4A52-A3A4-326DE52337D8Q30687449-DC97FDBA-1DD9-4CFE-B4EE-C136ED00F108Q33650105-DB43BC14-C578-4D8D-8C99-3B2832FA2699Q33690643-8BDD4A36-C614-4CE5-92F1-CD4357F1608BQ33959264-A5928A29-2880-459B-B10F-F721419DB6F3Q33976048-5C06637E-F47D-4D33-9B4C-1587E53D1269Q34104766-F72F6D48-5112-439E-B8E9-298D9A282E08Q34136701-8820428A-AE1C-49CE-9625-1385A4599C1CQ34182267-8E08F20C-40EA-46D7-89A3-B6A9BBA48FC6Q34183291-CB61A3C3-40AC-486C-B481-C102A120565AQ34284268-3A0FA9ED-0EA4-4A55-8FA4-1D9D92F45D68Q34607789-70B76D1D-C761-409B-A7F7-CBEEB7827E1FQ34768480-D517CF73-E2AD-411F-A079-6C59E6FD6AD7Q34910933-D30B6EB6-8D9D-4566-92BE-D9D5475E73A8Q35132552-BC27A30E-3C4B-47E5-ACB0-3387C1AC8AD6Q35628309-36FE77BF-4EF7-415E-A418-87831A85FF48Q36314106-4CC5C49F-5F6A-46D8-9933-3D7C82D86E63Q36627264-51A12501-CA08-4CB9-A432-57D4E8F6029DQ36968140-C23F689A-3A96-4442-BB52-3DD8501C8412Q37091704-0D2549BB-F268-4159-89F1-ACB2863376E7Q37164085-FB0DB993-D34A-44A5-AE91-5C1EB02CCFF1Q37393668-96DBE2E1-229E-4311-95C9-2DF90C2B6EA5Q37638380-CD675673-7951-43F7-97B7-F6715C14D36CQ37688257-3E5E4BBF-F060-479D-8792-B4EEB24F47C7Q37814173-6A785BF7-4578-4EA2-83F1-6AE8B98CABB3Q37909774-C94EDDEF-D304-4F9F-952A-DA14C8E79478Q38108468-3421623D-0C44-4E9B-89E2-C3AB3EE7748EQ38738090-EECC9267-0F1B-4C3F-BBE1-1BF09852762DQ38887735-9281367A-543C-4EA8-82DE-D7F2A3E2E6D9Q39475167-54897A7F-4CF9-4CCC-ABD3-9EF7B4E9074DQ39558155-48549D07-B78A-45CA-97AC-160A389D7B07Q39964396-DA6C7BBF-28D0-4EB4-AB0E-62A793C9CCA9Q40014363-3E970FB5-B176-4BDA-8068-50C450D24204Q41594983-504D4AB4-5C83-4C35-98E4-7D2E89B68ED2Q42584304-A178F8E6-5229-408E-9C51-7FE52F077A83Q42772696-A9877EAF-E28B-4BA6-BCF7-3118AB8347F4Q43169471-EE0D06F5-FAC6-4CF9-9CD8-196A21D87D1F
P2860
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Itraconazole treatment of diss ...... me. AIDS Clinical Trial Group.
@en
type
label
Itraconazole treatment of diss ...... me. AIDS Clinical Trial Group.
@en
prefLabel
Itraconazole treatment of diss ...... me. AIDS Clinical Trial Group.
@en
P2093
P1476
Itraconazole treatment of diss ...... ome. AIDS Clinical Trial Group
@en
P2093
P304
P356
10.1016/S0002-9343(99)80311-8
P407
P577
1995-04-01T00:00:00Z